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Introduction
Colorectal cancer (CRC) is the most common gastrointesti-
nal cancer worldwide, the third most commonly diagnosed 
malignancy and fourth cause of deaths due to neoplasms [1]. 
Men are more susceptible to develop CRC than women [1, 
2]. It is estimated that in 2017 135,430 new patients will be 
diagnosed with CRC worldwide [3]. Five-year survival rates 
depend mostly on the stage of cancer. The localized dis-
ease is found in less than 40% of primary diagnoses, where 
5-year survival rates reach nearly 90%. When the disease is 
regionally advanced (spread to regional lymph nodes), over 
70% of patients will survive 5 years. In stage IV with distant 
metastases, which is found relatively often (more than 20% 
of primary diagnoses), overall 5-year survival is less than 
14% (or even less in rectal cancer cases) [3]. Long-term 
survival exceeding 5 years in disease with distant metastases 
was 9% when treated only with palliative chemotherapy and 
36% when surgical and systemic treatment was combined [4, 
5]. Therefore, aggressive surgical treatment has been proved 
to bring advantage in all patients eligible for radical metas-
tasectomy [6, 7].
In 2013, a consensus of multidisciplinary management 
of CRC has been achieved and EURECCA guidelines have 
been published. Together with 2016 ESMO guidelines and 
ASCRS guidelines, they provide a standard of colorectal 
cancer treatment [8–10]. The fundamentals of treatment 
have been similar for years. Treatment should be provided 
by a multidisciplinary team of surgeons, medical oncolo-
gists, pathologists, radiation oncologists and radiologists. 
At the very beginning, it is crucial to assess the resectability 
criteria [9]. When considering management of CRC, locali-
zation, size of the primary tumor and all metastases as well 
as patient’s general health condition should be considered.
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If the CRC stage allows radical resection of the primary 
tumor, with no doubt, R0 surgery is an upfront treatment 
option. In majority of rectal cancer cases neoadjuvant radi-
otherapy or radio-chemotherapy should be pondered [8]. 
Initially unresectable disease (both primary tumor and/or 
metastases) may become resectable after applying systemic 
treatment. This procedure is known as conversion therapy 
and has been proved to maintain better long-term outcomes 
than chemotherapy alone [9, 11].
The group of metastatic patients is highly heterogene-
ous, and each case should be considered separately. In 2016, 
Franko et al. [12] published an article in which they prove 
that localization of metastases influences survival rates. 
Patients with only lung metastases have significantly bet-
ter overall survival rates than those with liver metastases, 
while patients with peritoneal spread have the worst prog-
nosis. The analysis also showed that patients with one-organ 
non-peritoneal metastases have the best prognosis and the 
worst concerns patients with non-isolated peritoneal metas-
tases [12]. Metastasectomy (as long as R0 resection can be 
achieved) has been performed to cure metastatic disease 
in the liver and lung more frequently for colorectal cancer 
metastases than for any other malignant neoplasms [13]. 
Whether those metastases are synchronous or metachronous 
is also of great importance, because metachronous hepatic 
and pulmonary resection has significantly better survival 
compared to the synchronous [14].
Nevertheless, combining both extensive and multivisceral 
surgical resections with preoperative or perioperative sys-
temic drugs can lengthen survival in the majority of patients 
and even permanent cure in some cases is possible [15].
Local recurrences (more frequent when the primary 
tumor origins from rectum, where achieving clear resec-
tion margins is more complex) reduced significantly since 
the introduction of total mesorectal excision and complete 
mesocolic excision [16, 17]. Extended resections or pelvic 
exenterations often require expertise from other specialties 
(for example, urology, orthopedic surgery, plastic surgery 
or gynecology) [18]. Managing with recurrent disease is a 
challenge for today surgeons; however, it is inherent and 
inevitable part of advanced cancer treatment. This leads to a 
conclusion that all attempts should be undertaken to achieve 
R0 resections, and surgical intervention should be pondered 
as it affects patients’ survival.
Treatment of unresectable disease
In approximately 65% of patients with stage IV CRC, a 
radical surgery is not possible [19]. In those cases, the issue 
that comes to the forefront is whether the disease is symp-
tomatic or not. Up to 6% of stage IV CRC patients represent 
emergency conditions, such as active or occult bleeding, 
perforation or mechanical bowel obstruction [19, 20]. These 
individuals for obvious reasons require surgical interven-
tion. This may simply prolong survival or improve patients’ 
general health condition and enable subsequent palliative 
systemic treatment. Moreover, it also impacts patients’ qual-
ity of life [9].
But what about resection in asymptomatic unresect-
able patients? Recent guidelines—EURECCA, ESMO 
and ASCRS—advise not to perform primary tumor resec-
tion (PTR) in asymptomatic cases with metastases that are 
beyond possibilities of surgical treatment [8–10]. Many 
points in the currently effective guidelines have been formed 
based on a 2012 Cochrane systematic review by Cirocchi 
et al. [19] in which they found that resection of the primary 
tumor in unresectable stage IV asymptomatic patients (who 
are managed with chemo- or radiotherapy) does not influ-
ence overall survival. Also, although resection does reduce 
the risk of tumor-related complications, these are relatively 
uncommon making them less clinically important. In addi-
tion, there is no point in delaying systemic treatment admin-
istration. These conclusions were based on the analysis of 
7 studies (1086 patients; 722 patients treated with primary 
tumor resection and 364 patients managed first with chemo-
therapy and/or radiotherapy). However, the risk of selection, 
channeling or performance bias is significant, because none 
of those articles was based on a randomized trial. Studied 
groups differed in the type of surgery and were not homog-
enous in the patients’ recruitment. In the group where resec-
tion was performed, the size and localization of metastases 
was more favorable. What is more, authors agree that there 
still is enough doubt with regard to the published literature 
to justify further clinical trials in this area [19].
Chemotherapy development over the years also had a sig-
nificant impact on decision making. Population-based study 
by Hu et al. [21] demonstrated that although primary tumor 
resection rate in stage IV CRC patients has been decreas-
ing since 1990s, median relative survival rate has increased 
with annual percentage growth of 2.18% in 1988–2001 and 
5.43% in 2001–2009. This study compared 64,157 patients 
with stage IV colorectal cancer using data from national 
cancer registry. Authors suggest that these findings strongly 
coincide with advantages in chemotherapeutic agents that 
started after 2000. Recent studies confirm this shift in deci-
sion making, demonstrating the use of newer chemothera-
peutic agents and that these changes are associated with 
improved survival [22]. Modern, triple-drug chemotherapy 
has also been associated with reduced need of palliative 
surgery when compared to conventional 5-fluorouracil-
based chemotherapy (20% vs. 10%) [23]. Chemotherapy is 
even more convincing when comparing overall survival in 
patients treated with modern systemic agents [24] in com-
parison with old fluorouracil and leukovorin approach [25] 
(over 29 vs. 4.3 months).
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Another question is: will delaying the chemotherapy 
in order to perform a surgery influence the survival? The 
more demanding and complicated surgery, the more fre-
quent occurrence of serious complications. Postponing the 
introduction of systemic treatment for eight or even 4 weeks 
significantly decreased both overall and disease-free survival 
rates [26, 27].
Latest literature reviews and meta‑analyses 
supporting primary tumor resection
In few recent years, there have been a few reviews that could 
change current perspective on decision making in stage IV 
CRC. Some papers report survival benefit when patients 
underwent primary tumor resections (PTR); however, 
these are cohort studies that use propensity score-matched 
approach, which may be a limitation [28]. Meta-analysis by 
Clancy et al. [29] showed longer OS when primary tumor 
resection approach was used. This meta-analysis included 21 
papers, with over 44 thousand patients, that compared resec-
tion and chemotherapy in colorectal cancer with unresect-
able metastases. Most of included papers were retrospective 
reviews, while only two were cohort studies [30, 31]. As a 
result, PTR was associated with lower mortality risk (OR 
0.28; 95% CI 0.165–0.474) and 6.4 months longer median 
overall survival.
A pooled post hoc analysis by Feo et al. [32] of four rand-
omized trials confirms this correlation—PTR is in fact asso-
ciated with longer OS in multivariate analysis (median 19.2 
vs. 13.3 months—RCTs from 1997 to 2008). All authors are 
very careful when commenting positive results. Pezold et al. 
[33] did a systematic review of papers published between 
2010 and 2015, and, although, there are few papers showing 
benefit with PTR, authors say that retrospective studies with 
multiple limitations and possible bias are not enough to say 
straightforward whether this is the correct approach. This 
is because PTR is often chosen as a treatment of choice for 
patients with tumors smaller and localized in colon.
It is worth mentioning that there are studies showing 
sometimes systemic treatment is only effective when follow-
ing primary tumor resection. Ghiringhelli et al. [34] showed 
that the survival benefit of bevacizumab in 409 patients with 
metastatic CRC was only present in patients who underwent 
PTR previously.
The topic of performing randomized controlled trials has 
been recently brought back due to publication of new trial 
results. A study by Faron et al. analyzed data on 810 patients 
(478 in resection vs. 332 in non-resection group) from four 
first-line chemotherapy randomized trials. The analysis 
showed that primary tumor resection was independently 
associated with better overall and progression-free survival 
[35]. Ahmed et al. in retrospective cohort study compared 
patients who underwent surgical resection of primary tumor 
and received chemotherapy with patients treated with chem-
otherapy alone. Median overall survival in these groups 
was 18.3 and 8.4 months, respectively [36]. The analysis 
of 11,716 chemotherapy-treated stage IV colorectal cancer 
patients in California Cancer Registry was performed and 
published in 2014 by Tsang et al. Study showed that surgery 
was linked to higher median overall and colorectal cancer-
specific survival (21 vs. 10 months and 22 vs. 12 months, 
respectively—in surgery vs. no surgery groups) [37].
Many reviews in the field underline the need of quality 
of life data [38, 39] which has been neglected by authors 
of previously conducted studies. Fortunately, some rand-
omized controlled trials currently running have quality of 
life as their secondary outcome, including CAIRO4 study 
(NCT01606098), Spanish CCRe-IV study (NCT02015923) 
and GRECCAR8 study (NCT02314182).
Surgical techniques in primary tumor resections
Considering the legitimacy of removing the primary tumor, 
we have to keep in mind that the incidence of surgical com-
plications is high. What is more, there are significant differ-
ences in the difficulty of rectum versus colon procedures, 
which is reflected in the higher complication risk, longer 
length of hospital stay and slower recovery [40].
Although the rate of complications is comparable, their 
severity is different. Rectal resections are more for example 
commonly associated with higher-grade complications such 
as anastomotic leakage. It is of a great significance because 
the recovery after seriously complicated colorectal resection 
can affect the introduction of palliative chemotherapy which 
may have impact on survival. Therefore, in majority of cases 
even though primary tumor resection is performed, patients 
end up with colostomy rather than primary anastomosis. 
This obviously influences their quality of life. Accordingly, 
the decision about rectal resection has to be carefully dis-
cussed with the patient. Another question, besides whether 
to resect the tumor, is what surgical approach should be cho-
sen. Similarly, there are no clear answers. From the point 
of view of oncologic outcomes, most recent meta-analyses 
show that laparoscopic approach is not inferior to open 
surgery both short term and long term [41]. However, this 
aspect seems irrelevant in patients with metastatic disease in 
whom R0 resection is not possible. Also, there are benefits 
connected directly to using minimally invasive approach. It 
has been proven multiple times that laparoscopy results in 
less surgical trauma, quicker recovery and—most impor-
tantly—much lower complications rate [42, 43]. All of this 
is especially important since primary tumor resection leads 
to approximately 5 weeks of delay in chemotherapy initia-
tion [44], so approaches that allow its earlier start should be 
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more beneficial. Some authors point out that—as a general 
rule—minimally invasive techniques should be used when 
available [45].
To additionally improve postoperative course, it is sug-
gested to implement protocols of enhanced recovery after 
surgery (ERAS). Studies show that patients that follow 
ERAS protocol after colorectal surgery have lower compli-
cation rates and shorter length of hospital stay [46]. What 
is important in this case, it has been proven that ERAS pro-
tocol is also feasible for patients with stage IV colorectal 
cancer and there are no significant differences in morbidity, 
length of stay or readmissions rate between stages I–III and 
stage IV patients [47, 48].
How would randomized controlled trials change 
our decision making?
Although the discussion about this specific problem has been 
going on for several years now, there are still no randomized 
controlled trials to give any sort of quantitative results that 
could decide which approach is dominant. There have been 
several attempts to conduct such studies, and some of them 
are currently running; however, it is relatively difficult to 
recruit patients to appropriate groups, which has been proved 
in example by previously designed trials that failed to do so 
(NCT01086618, NCT01978249—termination by problems 
with enrollment).
Difficulty of randomization is attempted to be by-passed 
by running cohort studies with propensity score matching, 
which—although being a fair replacement—has some draw-
backs. Some may ask whether randomized controlled trials 
would change our approach to making decisions in this field. 
One thing that might be crucial is the fact that currently run-
ning studies are examining quality of life as their secondary 
outcome. This has been neglected previously, which resulted 
in this discussion.
There is a need for advanced prediction tools that would 
assist multidisciplinary teams in reaching treatment consen-
sus. Previously, predictive models that have been created 
focused on hepatic resection for metastatic colorectal cancer 
[49–51], and only recently a model for predicting recurrence 
and survival in patients undergoing concurrent curative 
resection has been described [52]. Another aspect that might 
lead us into personalized, predictive medicine is utilizing 
knowledge about gene mutations, metabolic pathways and 
their impact on colorectal cancer development [53]. It has 
been shown that there are differences in, i.e., BRAF gene 
mutations between early- and late-stage patients [54, 55]. 
That information, along with advanced bioinformatics analy-
sis, could help in creating accurate predictive models [56].
The problem of quality of life (QOL) improvement or 
deterioration is an underestimated but immensely important 
issue. Although QOL correction is one of the main concerns 
of palliative treatment, when compared with survival it is 
pushed to the background. There is still lack of trials assess-
ing QOL in advanced cancer patients. In our opinion, the 
decision whether to ultimately exclude patient from surgical 
treatment should be made after deep and full of understand-
ing of each patient’s needs.
Conclusions
Looking at the most recent meta-analyses, more and more 
authors point out that there is a trend toward performing pri-
mary tumor resections. Still, we are not able to say definitely 
where and when to choose it over chemotherapy upfront, 
especially without data on quality of life. Hopefully, results 
from currently running controlled randomized trials will 
somehow aid decision making in the future. For now, this 
choice is primarily up to surgeon’s experience, patients’ 
preferences and common sense.
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